Turner Judith A, Shortreed Susan M, Saunders Kathleen W, LeResche Linda, Thielke Stephen, Von Korff Michael
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.
Group Health Research Institute, Seattle, WA, USA.
Pain. 2016 Oct;157(10):2208-2216. doi: 10.1097/j.pain.0000000000000631.
Many consider chronic opioid therapy (COT) to be ineffective for fibromyalgia, but empirical evidence is limited. Among patients identified as initiating COT, we examined whether fibromyalgia was associated with different relationships of opioid use to pain and activity interference outcomes 12 months later. We obtained electronic data on diagnoses and opioid prescriptions. We obtained patient self-report data, including pain and activity interference measures, at baseline, 4 months, and 12 months. Among 1218 patients, 429 (35%) met our definition of fibromyalgia. Patients with and without fibromyalgia who had intermittent/lower-dose or regular/higher-dose opioid use at 12 months had similar 12-month pain intensity scores. However, among patients with minimal/no opioid use at 12 months, 12-month pain intensity was greater for those with fibromyalgia (adjusted mean = 5.15 [95% confidence interval, 4.80-5.51]; 0-10 scale) than for those without (4.44 [4.15-4.72]). Similar patterns were observed for 12-month activity interference. Among patients who discontinued opioids by 12 months, those with fibromyalgia were more likely to report bothersome side effects and less likely to report pain improvement as important reasons for discontinuation (P < 0.05). In sum, at 12 months, among patients who had discontinued opioids or used them minimally, those with fibromyalgia had worse outcomes and were less likely to have discontinued because of pain improvement. Among patients continuing COT, pain and activity interference outcomes were worse than those of patients with minimal/no opioid use and did not differ for those with fibromyalgia vs those with diverse other chronic pain conditions.
许多人认为慢性阿片类药物治疗(COT)对纤维肌痛无效,但实证证据有限。在确定开始接受COT治疗的患者中,我们研究了12个月后纤维肌痛是否与阿片类药物使用与疼痛和活动干扰结果之间的不同关系相关。我们获取了诊断和阿片类药物处方的电子数据。我们在基线、4个月和12个月时获取了患者的自我报告数据,包括疼痛和活动干扰测量数据。在1218名患者中,429名(35%)符合我们对纤维肌痛的定义。在12个月时使用间歇性/低剂量或常规/高剂量阿片类药物的纤维肌痛患者和非纤维肌痛患者,其12个月时的疼痛强度评分相似。然而,在12个月时极少使用/未使用阿片类药物的患者中,纤维肌痛患者的12个月疼痛强度(调整后均值 = 5.15 [95%置信区间,4.80 - 5.51];0 - 10分制)高于非纤维肌痛患者(4.44 [4.15 - 4.72])。12个月时的活动干扰情况也观察到类似模式。在12个月时停用阿片类药物的患者中,纤维肌痛患者更有可能报告令人烦恼的副作用,而因疼痛改善作为停药重要原因的可能性较小(P < 0.05)。总之,在12个月时,在已停用阿片类药物或极少使用阿片类药物的患者中,纤维肌痛患者的结局更差,且因疼痛改善而停药的可能性较小。在继续接受COT治疗的患者中,疼痛和活动干扰结局比极少使用/未使用阿片类药物的患者更差,且纤维肌痛患者与其他各种慢性疼痛疾病患者之间并无差异。